- Home
- NKSH vs FENC Comparison
NKSH vs FENC Comparison
Compare NKSH & FENC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NKSH | FENC |
|---|---|---|
| Founded | 1891 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 210.1M | 276.3M |
| IPO Year | N/A | 2001 |
Fundamental Metrics
Financial Performance| Metric | NKSH | FENC |
|---|---|---|
| Price | $35.94 | $7.80 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $15.00 |
| AVG Volume (30 Days) | 13.4K | ★ 180.0K |
| Earning Date | 01-23-2026 | 03-09-2026 |
| Dividend Yield | ★ 4.24% | N/A |
| EPS Growth | ★ 41.35 | N/A |
| EPS | ★ 2.04 | N/A |
| Revenue | ★ $51,980,000.00 | $38,790,000.00 |
| Revenue This Year | $2.95 | N/A |
| Revenue Next Year | $9.97 | $70.78 |
| P/E Ratio | $17.44 | ★ N/A |
| Revenue Growth | ★ 19.63 | N/A |
| 52 Week Low | $23.75 | $4.68 |
| 52 Week High | $35.71 | $9.92 |
Technical Indicators
Market Signals| Indicator | NKSH | FENC |
|---|---|---|
| Relative Strength Index (RSI) | 70.28 | 54.28 |
| Support Level | $33.72 | $7.35 |
| Resistance Level | $34.85 | $7.82 |
| Average True Range (ATR) | 0.83 | 0.33 |
| MACD | 0.11 | 0.03 |
| Stochastic Oscillator | 90.45 | 63.16 |
Price Performance
Historical ComparisonAbout NKSH National Bankshares Inc.
National Bankshares Inc is a bank holding company. It focuses on lending to small and mid-sized businesses and individuals. The types of loans it offers include commercial and agricultural, commercial real estate, construction for commercial and residential properties, residential real estate, home equity, and various consumer loan products. It also operates an insurance and brokerage subsidiary, National Bankshares Financial Services, Inc. The company earns its revenues from interest and fees on loans, non-interest income, and investments.
About FENC Fennec Pharmaceuticals Inc.
Fennec Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin-induced hearing loss, or ototoxicity in children. The company principally operates in the United States.